Neutrophil-mediated IL-6 receptor trans-signaling and the risk of chronic obstructive pulmonary disease and asthma

DSpace/Manakin Repository

Neutrophil-mediated IL-6 receptor trans-signaling and the risk of chronic obstructive pulmonary disease and asthma

Citable link to this page

 

 
Title: Neutrophil-mediated IL-6 receptor trans-signaling and the risk of chronic obstructive pulmonary disease and asthma
Author: Farahi, Neda; Paige, Ellie; Balla, Jozef; Prudence, Emily; Ferreira, Ricardo C.; Southwood, Mark; Appleby, Sarah L.; Bakke, Per; Gulsvik, Amund; Litonjua, Augusto A.; Sparrow, David; Silverman, Edwin K.; Cho, Michael H.; Danesh, John; Paul, Dirk S.; Freitag, Daniel F.; Chilvers, Edwin R.

Note: Order does not necessarily reflect citation order of authors.

Citation: Farahi, N., E. Paige, J. Balla, E. Prudence, R. C. Ferreira, M. Southwood, S. L. Appleby, et al. 2017. “Neutrophil-mediated IL-6 receptor trans-signaling and the risk of chronic obstructive pulmonary disease and asthma.” Human Molecular Genetics 26 (8): 1584-1596. doi:10.1093/hmg/ddx053. http://dx.doi.org/10.1093/hmg/ddx053.
Full Text & Related Files:
Abstract: Abstract The Asp358Ala variant in the interleukin-6 receptor (IL-6R) gene has been implicated in asthma, autoimmune and cardiovascular disorders, but its role in other respiratory conditions such as chronic obstructive pulmonary disease (COPD) has not been investigated. The aims of this study were to evaluate whether there is an association between Asp358Ala and COPD or asthma risk, and to explore the role of the Asp358Ala variant in sIL-6R shedding from neutrophils and its pro-inflammatory effects in the lung. We undertook logistic regression using data from the UK Biobank and the ECLIPSE COPD cohort. Results were meta-analyzed with summary data from a further three COPD cohorts (7,519 total cases and 35,653 total controls), showing no association between Asp358Ala and COPD (OR = 1.02 [95% CI: 0.96, 1.07]). Data from the UK Biobank showed a positive association between the Asp358Ala variant and atopic asthma (OR = 1.07 [1.01, 1.13]). In a series of in vitro studies using blood samples from 37 participants, we found that shedding of sIL-6R from neutrophils was greater in carriers of the Asp358Ala minor allele than in non-carriers. Human pulmonary artery endothelial cells cultured with serum from homozygous carriers showed an increase in MCP-1 release in carriers of the minor allele, with the difference eliminated upon addition of tocilizumab. In conclusion, there is evidence that neutrophils may be an important source of sIL-6R in the lungs, and the Asp358Ala variant may have pro-inflammatory effects in lung cells. However, we were unable to identify evidence for an association between Asp358Ala and COPD.
Published Version: doi:10.1093/hmg/ddx053
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5393150/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:32630517
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters